Serum HER2 testing in patients with HER2-positive breast cancer: the death knell tolls.

Leyland-Jones, Brian; Smith, Brian R

Leyland-Jones, Brian; Smith, Brian R.

Affiliation

Leyland-Jones B; Emory Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA. leyland@emory.edu

Lancet Oncol ; 12(3): 286-95, 2011 Mar.

Article in En | MEDLINE | ID: mdl-21376291

Subject(s)

Biomarkers, Tumor/analysis; Breast Neoplasms/metabolism; Receptor, ErbB-2/analysis; Breast Neoplasms/drug therapy; Breast Neoplasms/pathology; Female; Humans; Prognosis; Receptor, ErbB-2/biosynthesis

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Biomarkers, Tumor / Receptor, ErbB-2 Type of study: Guideline / Prognostic_studies / Risk_factors_studies Limits: Female / Humans Language: En Journal: Lancet Oncol Journal subject: NEOPLASIAS Year: 2011 Type: Article Affiliation country: United States

Fulltext

XML

PubMed Links

Search on Google